Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)

Ductal Carcinoma in Situ: Clinical Perspective

(2010) Thorsten Kühn   Breast Care

Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer

(2010) H Wong et al.   BRITISH JOURNAL OF CANCER

Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast

(2010) Henry M. Kuerer et al.   CANCER

Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer

(2010) V. Guarneri et al.   CANCER TREATMENT REVIEWS

Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study

(2010) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

(2010) Michael Untch et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

(2010) Luca Gianni et al.   LANCET

Genomic Differences Between Pure Ductal Carcinoma In Situ of the Breast and that Associated with Invasive Disease: a Calibrated aCGH Study

(2008) V. V. Iakovlev et al.   CLINICAL CANCER RESEARCH

Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization

(2008) Yuxia Gao et al.   JOURNAL OF MOLECULAR MEDICINE-JMM